Portale Epatite e malattie del fegato
Sito Epatite B
Sito Steatosi
Sito Cirrosi
Sito Tumori
Sito Trapianti
Nuovi Farmaci
Malattie autoimmuni

Studi scientifici principali



    1. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889–98. (ION-1)

    2. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370:1483–93. (ION-2)

    3. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879–88. (ION-3)

    4. Naggie S et al. Ledipasvir and sofosbuvir for 12 weeks in patients coinfected with HCv and HIV-1. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). 2015. (ION-4)

    5. Gane EJ et al. High Efficacy of LDV/SOF Regimens for 12 Weeks for Patients With HCV Genotype 3 or 6 Infection AASLD, 2014, Poster #LB-11 (ELECTRON-2)

    6. Gane EJ et al. Ledipasvir/Sofosbuvir ± Ribavirin in Difficult-to-Treat HCV Populations. EASL, 2014, Oral #6 (ELECTRON-2)

    7. Kapoor R et al. Treatment of Hepatitis C Genotype 4 with Ledipasvir and Sofosbuvir for 12 weeks: Results of the SYNERGY Trial. AASLD, 2014, Oral #240

    8. Charlton M et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease. Gastroenterology 2015 (epub ahead of print) (SOLAR-1)

    9. Manns M et al. Ledipasvir/Sofosbuvir With Ribavirin is Safe and Efficacious in Decompensated and Post-Liver Transplantation Patients With HCV Infection: Preliminary Results of the SOLAR-2 Trial, EASL, 2015, Oral presentation GO2;

    10. Osinusi et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31;313(12):1232-9

    11. Harvoni: Riassunto delle Caratteristiche del Prodotto


Vuoi ricevere aggiornamenti su questo argomento? Iscriviti alla Newsletter!